A detailed history of Pnc Financial Services Group, Inc. transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Pnc Financial Services Group, Inc. holds 150 shares of ZNTL stock, worth $288. This represents 0.0% of its overall portfolio holdings.

Number of Shares
150
Previous 22 581.82%
Holding current value
$288
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 07, 2025

BUY
$2.7 - $4.03 $345 - $515
128 Added 581.82%
150 $0
Q2 2024

Aug 09, 2024

BUY
$4.09 - $16.13 $89 - $354
22 New
22 $0
Q1 2022

May 12, 2022

SELL
$41.58 - $80.89 $665 - $1,294
-16 Closed
0 $0
Q3 2021

Nov 05, 2021

BUY
$46.83 - $73.5 $749 - $1,176
16 New
16 $1,000

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $109M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Pnc Financial Services Group, Inc. Portfolio

Follow Pnc Financial Services Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.